The one-shot vaccine, developed by Panacea Biotec and branded as DengiAll, is being tested through a multi-centre, ...

Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed ...

ICMR and Panacea Biotec conduct third phase trials for indigenous dengue vaccine in India with promising results.

For years now, scientists have tried to develop a safe and effective dengue vaccine. The challenge however, is that there are four different types of dengue viruses, and a common vaccine must protect ...

Kennedy’s decision to replace ACIP wholesale and the comments he has made about deviating from standard vaccine policymaking ...

The enrolment for phase III clinical trials of India's first dengue vaccine, DengiAll, is expected to be completed by October ...

An ongoing Phase III clinical trial of DengiAll, a one-shot dengue vaccine developed by Panacea Biotec, is progressing in ...

The phase III clinical trial enrolment for India's first one-shot dengue vaccine, DengiAll, developed by Panacea Biotec, is set to complete with 10,500 participants across 20 centers. This trial aims ...

Teams from various departments have sprung into action to prevent and control vector-borne diseases like dengue, malaria, and ...

Phase-III trial of indigenous one-shot dengue vaccine by Panacea Biotec shows promising results in India, aiming for ...